Vaccine (Peptide vaccine) · Immune activation, directed at tumor-associated peptide antigens expressed in renal cell carcinoma · developed by Immatics Biotechnologies GmbH
IMA901 is a multipeptide cancer vaccine made of 10 synthetic tumor-associated peptide antigens, nine binding HLA class I and one binding HLA class II. It is designed to increase cytotoxic T-lymphocyte responses against renal cell carcinoma cells expressing these peptides. It is studied in renal cell carcinoma and metastatic renal cell carcinoma, given with intradermal GM-CSF and cyclophosphamide in some regimens.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01265901 | Phase 3 | Metastatic Renal Cell Carcinoma | Completed | IMTX |
| NCT00523159 | Phase 2 | Renal Cell Carcinoma | Completed | IMTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic Renal Cell CarcinomaRenal Cell Carcinoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.
See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMTX catalysts and pipeline →